RETEVMO DIN 02565668
Health Canada record
| Active ingredient(s) | SELPERCATINIB 40 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EX22 SELPERCATINIB |
| Original market date | |
| Current status date | 06-Feb-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Eli Lilly Canada Inc. — licence 100164, currently licensed, last inspection rating C (2026-03-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SELPERCATINIB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02516918 | RETEVMO | ELI LILLY CANADA INC | Capsule | SELPERCATINIB 40 MG | Marketed |
| 02516926 | RETEVMO | ELI LILLY CANADA INC | Capsule | SELPERCATINIB 80 MG | Marketed |
| 02565676 | RETEVMO | ELI LILLY CANADA INC | Tablet | SELPERCATINIB 80 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36852 | 2026-02-06 | Supplement to a New Drug Submission (SNDS) | Product Monograph reformatted to the Master Template. Addition of new dosage form: Tablet. |
International API supply for SELPERCATINIB
1 active FDA Drug Master Files.
Request a quote for RETEVMO